Jamp Pharma Group, a Canadian-owned pharmaceutical company based in Montréal, launched Guanfacine XR, a generic version of the reference product INTUNIV XR® from Takeda Canada Inc. that treats attention deficit hyperactivity disorder (ADHD). The introduction of this generic drug, which offers the same quality and is more affordable, will make treatment more accessible to patients and significantly reduce costs for public and private drug plans.
It's the first product launched in a series of many drugs to treat attention deficit hyperactivity disorder (ADHD). JAMP Pharma Group plans to offer a wide range of products to meet the specific needs of patients in terms of drug size and appearance. The cost associated with ADHD across all ages is estimated to exceed $7 billion each year in Canada1, and JAMP Pharma Group intends to produce generic versions of many of these niche products in the coming years. Patients and healthcare professionals can expect more ADHD drug options and a reliable supply chain.